OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 BA.1/BA.2 lineages among adults and adolescents in a multicentre primary care study, Europe, December 2021 to June 2022
Charlotte Lanièce Delaunay, Iván Martínez‐Baz, Noémie Sève, et al.
Eurosurveillance (2024) Vol. 29, Iss. 13
Open Access | Times Cited: 6
Charlotte Lanièce Delaunay, Iván Martínez‐Baz, Noémie Sève, et al.
Eurosurveillance (2024) Vol. 29, Iss. 13
Open Access | Times Cited: 6
Showing 6 citing articles:
COVID-19 Vaccine Effectiveness in Autumn and Winter 2022 to 2023 Among Older Europeans
Charlotte Lanièce Delaunay, Clara Mazagatos, Iván Martínez‐Baz, et al.
JAMA Network Open (2024) Vol. 7, Iss. 7, pp. e2419258-e2419258
Open Access | Times Cited: 2
Charlotte Lanièce Delaunay, Clara Mazagatos, Iván Martínez‐Baz, et al.
JAMA Network Open (2024) Vol. 7, Iss. 7, pp. e2419258-e2419258
Open Access | Times Cited: 2
Hybrid Immunity and the Incidence of SARS-CoV-2 Reinfections during the Omicron Era in Frontline Healthcare Workers
Carmen-Daniela Chivu, Maria Crăciun, Daniela Pițigoi, et al.
Vaccines (2024) Vol. 12, Iss. 6, pp. 682-682
Open Access | Times Cited: 1
Carmen-Daniela Chivu, Maria Crăciun, Daniela Pițigoi, et al.
Vaccines (2024) Vol. 12, Iss. 6, pp. 682-682
Open Access | Times Cited: 1
Vaccine Effectiveness against GP-Attended Symptomatic COVID-19 and Hybrid Immunity among Adults in Hungary during the 2022–2023 Respiratory Season Dominated by Different SARS-CoV-2 Omicron Subvariants
J Horváth, Gergő Túri, Katalin Krisztalovics, et al.
Vaccines (2024) Vol. 12, Iss. 5, pp. 496-496
Open Access
J Horváth, Gergő Túri, Katalin Krisztalovics, et al.
Vaccines (2024) Vol. 12, Iss. 5, pp. 496-496
Open Access
Durability for 12 months of antibody response to a booster dose of monovalent BNT162b2 in adults who had initially received 2 doses of inactivated vaccine
Eunice Y. C. Shiu, Samuel M. S. Cheng, Mario Martín-Sánchez, et al.
Vaccine (2024) Vol. 42, Iss. 26, pp. 126317-126317
Closed Access
Eunice Y. C. Shiu, Samuel M. S. Cheng, Mario Martín-Sánchez, et al.
Vaccine (2024) Vol. 42, Iss. 26, pp. 126317-126317
Closed Access
Effectiveness of XBB.1.5 Vaccines Against Symptomatic SARS‐CoV‐2 Infection in Older Adults During the JN.1 Lineage‐Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023–1 March 2024
Lore Merdrignac, Charlotte Lanièce Delaunay, Nuno Verdasca, et al.
Influenza and Other Respiratory Viruses (2024) Vol. 18, Iss. 11
Open Access
Lore Merdrignac, Charlotte Lanièce Delaunay, Nuno Verdasca, et al.
Influenza and Other Respiratory Viruses (2024) Vol. 18, Iss. 11
Open Access
Bias in control selection associated with the use of rapid tests in influenza vaccine effectiveness studies
Eero Poukka, Caitriona Murphy, Loretta Mak, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Eero Poukka, Caitriona Murphy, Loretta Mak, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
